BACKGROUND AND PURPOSE: Haem oxygenase 1 (HO-1) is an inducible protein that plays a major protective role in conditions such as ischaemia-reperfusion injury and inflammation. In this study, we have investigated the role of haem arginate (HA) in human male subjects in the modulation of HO-1 expression and its correlation with the GT length polymorphism (GT(n)) in the promoter of the HO-1 gene. EXPERIMENTAL APPROACH: In a dose-escalation, randomized, placebo-controlled trial, seven healthy male subjects with a homozygous short (S/S) and eight with a long (L/L) GT(n) genotype receivedintravenous HA. HO-1 protein expression and mRNA levels in peripheral blood monocytes, bilirubin, haptoglobin, haemopexin and haem levels were analysed over a 48 h observation period. KEY RESULTS: We found that the baseline mRNA levels of HO-1 were higher in L/L subjects, while protein levels were higher in S/S subjects. HA induced a dose-dependent increase in the baseline corrected area under the curve values of HO-1 mRNA and protein over 48 h. The response of HO-1 mRNA was more pronounced in L/L subjects but the protein level was similar across the groups. CONCLUSIONS AND IMPLICATION: HA is an effective inducer of HO-1 in humans irrespective of the GT(n) genotype. The potential therapeutic application of HA needs to be evaluated in clinical trials.
RCT Entities:
BACKGROUND AND PURPOSE:Haem oxygenase 1 (HO-1) is an inducible protein that plays a major protective role in conditions such as ischaemia-reperfusion injury and inflammation. In this study, we have investigated the role of haem arginate (HA) in human male subjects in the modulation of HO-1 expression and its correlation with the GT length polymorphism (GT(n)) in the promoter of the HO-1 gene. EXPERIMENTAL APPROACH: In a dose-escalation, randomized, placebo-controlled trial, seven healthy male subjects with a homozygous short (S/S) and eight with a long (L/L) GT(n) genotype received intravenous HA. HO-1 protein expression and mRNA levels in peripheral blood monocytes, bilirubin, haptoglobin, haemopexin and haem levels were analysed over a 48 h observation period. KEY RESULTS: We found that the baseline mRNA levels of HO-1 were higher in L/L subjects, while protein levels were higher in S/S subjects. HA induced a dose-dependent increase in the baseline corrected area under the curve values of HO-1 mRNA and protein over 48 h. The response of HO-1 mRNA was more pronounced in L/L subjects but the protein level was similar across the groups. CONCLUSIONS AND IMPLICATION: HA is an effective inducer of HO-1 in humans irrespective of the GT(n) genotype. The potential therapeutic application of HA needs to be evaluated in clinical trials.
Authors: T Ishihara; M Kaito; K Takeuchi; E C Gabazza; Y Tanaka; K Higuchi; J Ikoma; S Watanabe; H Sato; Y Adachi Journal: J Gastroenterol Hepatol Date: 2001-06 Impact factor: 4.029
Authors: A E Bharucha; A Kulkarni; K M Choi; M Camilleri; M Lempke; G J Brunn; S J Gibbons; A R Zinsmeister; G Farrugia Journal: Clin Pharmacol Ther Date: 2009-12-02 Impact factor: 6.875
Authors: Martin Schillinger; Markus Exner; Wolfgang Mlekusch; Hans Domanovits; Kurt Huber; Christine Mannhalter; Oswald Wagner; Erich Minar Journal: Thromb Res Date: 2002-04-15 Impact factor: 3.944
Authors: Joanne T Marsden; Simon Guppy; Penelope Stein; Timothy M Cox; Michael Badminton; Tricia Gardiner; Julian H Barth; M Felicity Stewart; David C Rees Journal: JIMD Rep Date: 2015-03-12
Authors: Rochus A Neeleman; Margreet A E M Wagenmakers; Rita H Koole-Lesuis; G Sophie Mijnhout; J H Paul Wilson; Edith C H Friesema; Janneke G Langendonk Journal: J Inherit Metab Dis Date: 2018-04-19 Impact factor: 4.982
Authors: Martin Andreas; Albrecht Ingo Schmid; Daniel Doberer; Kiril Schewzow; Stefan Weisshaar; Georg Heinze; Martin Bilban; Ewald Moser; Michael Wolzt Journal: J Cardiovasc Magn Reson Date: 2012-08-02 Impact factor: 5.364
Authors: Uros Klickovic; Daniel Doberer; Ghazaleh Gouya; Stefan Aschauer; Stefan Weisshaar; Angela Storka; Martin Bilban; Michael Wolzt Journal: Biomed Res Int Date: 2014-01-29 Impact factor: 3.411